Affiliation:
1. First Affiliated Hospital of Soochow University
Abstract
Abstract
Objective: We conducted a preliminary statistical analysis of clinical and physical dosimetric factors of lung cancer patients who had previously undergone lung and/or mediastinal radiotherapy and died of or survived severe acute radiation pneumonitis (SARP). Our study was the first to reveal the heterogeneity in clinical factors, physical dosimetric factors, and SARP onset time that determined the clinical outcomes of lung cancer patients who developed SARP.
Materials and methods: The clinical characteristics, physical dosimetry factors, and SARP onset time of deceased and surviving patients were retrospectively analyzed. SPSS 20.0 was used for data analysis. A t-test was used for intergroup comparison, and a Mann–Whitney U test was used for data with skewed distribution. Qualitative data were represented using frequencies (%), and Fisher’s exact test or χ2 test was used for intergroup comparison of nonparametric data. Binary logistic analysis was used for univariate and multivariate analyses. Differences with a P<0.05 were considered statistically significant.
Results: Univariate analysis revealed that the potential predictors of SARP death were as follows: ipsilateral lung V5 and V30, contralateral lung V5, V10, and V30, total lung V5, V10, and V30, mean lung dose, mean heart dose, and maximum spinal cord dose. Multivariate analysis showed that ipsilateral lung V5 and total lung V5 were predictors that determined the final outcome of SARP patients. In addition, we analyzed the time from the completion of radiotherapy to SARP onset, and found significant difference between the two groups.
Conclusions: There was no decisive correlation between clinical characteristics and SARP outcome (i.e., death or survival) in lung radiotherapy patients. Ipsilateral lung V5 and total lung V5 were independent predictors of death in SARP patients.
Publisher
Research Square Platform LLC
Reference44 articles.
1. Raso MG, Bota-Rabassedas N. Wistuba, II, Pathology and Classification of SCLC.Cancers (Basel).13(4) (2021).
2. Wang Q, Gümüş ZH, Colarossi C, Memeo L, Wang X, Kong CY, Boffetta P. SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection.J Thorac Oncol. (2022).
3. Non-small-cell lung cancers: a heterogeneous set of diseases;Chen Z;Nat Rev Cancer,2014
4. The evolving role of radiotherapy in non-small cell lung cancer;Brown S;Br J Radiol,2019
5. Vinod SK, Hau E. Radiotherapy treatment for lung cancer: Current status and future directions.Respirology. 25 Suppl2 (2020)61–71.